Hodgkin Lymphoma (HL) Treatment and Our Challenges in Bangladesh
Open Access
- 6 May 2021
- journal article
- Published by Haematology Society of Bangladesh in Haematology Journal of Bangladesh
- Vol. 5 (01), 01-02
- https://doi.org/10.37545/haematoljbd202176
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialThe Lancet Haematology, 2020
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin LymphomaJAMA Oncology, 2020
- Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyBlood, 2020
- A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ LymphomasTransplantation and Cellular Therapy, 2019
- CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)Transplantation and Cellular Therapy, 2019
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseBlood, 2018
- Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 StudyBlood, 2017
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012